
PHARMACEUTICAL 2019

ARDELYX INC. Rank 208 of 371







PHARMACEUTICAL 2019

ARDELYX INC. Rank 208 of 371



The relative strengths and weaknesses of ARDELYX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARDELYX INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 167% points. The greatest weakness of ARDELYX INC. is the variable Research and Development, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is -194%, being 137% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	176,371
Cost of Goods Sold	466
Intangible Assets	0
Liabilities, Current	17,728
Liabilities, Non-Current	582
Other Assets	1,350
Other Compr. Net Income	9.0
Other Expenses	3,538
Other Liabilities	49,209
Other Net Income	3,187
Property and Equipment	5,611
Research and Development	69,373
Revenues	2,607
Selling, General and Administrative Expense	23,715

Output Variable	Value in 1000 USD
Assets	183,332
Liabilities	67,519
Expenses	97,092
Stockholders Equity	115,813
Net Income	-91,298
Comprehensive Net Income	-91,294
Economic Capital Ratio	-194%